• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.

作者信息

Singer Mendel E, Kaelber David C, Antonelli Maria J

机构信息

Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

出版信息

Ann Rheum Dis. 2022 Aug 11;81(9):e161. doi: 10.1136/annrheumdis-2020-218500.

DOI:10.1136/annrheumdis-2020-218500
PMID:32759263
Abstract
摘要

相似文献

1
Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.羟氯喹对狼疮和类风湿关节炎患者预防新冠病毒疾病无效。
Ann Rheum Dis. 2022 Aug 11;81(9):e161. doi: 10.1136/annrheumdis-2020-218500.
2
Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer .对辛格所著《羟氯喹对狼疮和类风湿关节炎患者预防新冠病毒无效》的回应
Ann Rheum Dis. 2022 Aug 11;81(9):e162. doi: 10.1136/annrheumdis-2020-218683.
3
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.羟氯喹可降低系统性红斑狼疮和类风湿关节炎患者的 Th17 相关细胞因子。
Clinics (Sao Paulo). 2013 Jun;68(6):766-71. doi: 10.6061/clinics/2013(06)07.
4
Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.羟氯喹治疗类风湿关节炎和系统性红斑狼疮患者对 COVID-19 发病风险的影响：一项多中心回顾性队列研究。
J Int Med Res. 2022 Apr;50(4):3000605221090363. doi: 10.1177/03000605221090363.
5
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.暴露前使用羟氯喹对新冠病毒疾病死亡率的影响：一项基于人群的队列研究，研究对象为使用OpenSAFELY平台的类风湿关节炎或系统性红斑狼疮患者
Lancet Rheumatol. 2021 Jan;3(1):e19-e27. doi: 10.1016/S2665-9913(20)30378-7. Epub 2020 Nov 5.
6
Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.羟氯喹视网膜病变风险的反应与系统性红斑狼疮或类风湿关节炎无关。
Doc Ophthalmol. 2018 Feb;136(1):95-96. doi: 10.1007/s10633-018-9624-3. Epub 2018 Jan 30.
7
Patients with lupus with COVID-19: University of Michigan experience.患有狼疮且感染新冠病毒的患者：密歇根大学的经验。
Ann Rheum Dis. 2021 Mar;80(3):e35. doi: 10.1136/annrheumdis-2020-217794. Epub 2020 May 31.
8
ISOLATION AND CHARACTERIZATION OF MYCOPLASMAS (PPLO) FROM PATIENTS WITH RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS AND REITER'S SYNDROME.从类风湿性关节炎、系统性红斑狼疮和赖特综合征患者中分离并鉴定支原体（类胸膜肺炎微生物）
Arthritis Rheum. 1965 Jun;8:376-88. doi: 10.1002/art.1780080306.
9
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.羟氯喹和氯喹在治疗系统性红斑狼疮、类风湿关节炎及相关疾病中的治疗和药理学特性。
Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.
10
Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.系统性红斑狼疮和类风湿关节炎患者中与羟氯喹相关的视网膜毒性
Doc Ophthalmol. 2017 Dec;135(3):187-194. doi: 10.1007/s10633-017-9607-9. Epub 2017 Aug 29.

引用本文的文献

1
Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.使用 Janus 激酶抑制剂与肿瘤坏死因子抑制剂治疗的类风湿关节炎患者按器官部位划分的癌症发病率比较：一项回顾性真实世界队列分析。
Biologics. 2025 Aug 30;19:525-538. doi: 10.2147/BTT.S532668. eCollection 2025.
2
Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.自身免疫性疾病和新冠肺炎作为不良预后的风险因素：来自西班牙全国性SEMI-COVID-19登记处的13940例住院患者数据
J Clin Med. 2021 Apr 23;10(9):1844. doi: 10.3390/jcm10091844.
3
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.
羟氯喹长期治疗对预防风湿性疾病患者新冠病毒病严重并发症无效。
Rheumatol Adv Pract. 2021 Mar 2;5(1):rkab014. doi: 10.1093/rap/rkab014. eCollection 2021.
4
Does hydroxychloroquine still have any role in the COVID-19 pandemic?羟氯喹在 COVID-19 大流行中还有作用吗？
Expert Opin Pharmacother. 2021 Jul;22(10):1257-1266. doi: 10.1080/14656566.2021.1898589. Epub 2021 Mar 16.
5
SARS-CoV-2 and Systemic Lupus Erythematosus.新型冠状病毒与系统性红斑狼疮。
Curr Rheumatol Rep. 2021 Jan 28;23(2):8. doi: 10.1007/s11926-020-00973-w.
6
Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19.干扰素和羟氯喹对COVID-19预防及早期治疗的潜力
J Cell Immunol. 2020;2(6):333-340. doi: 10.33696/immunology.2.063.
7
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease.COVID-19 与系统性红斑狼疮：炎症性疾病中的经验教训。
Transl Res. 2021 Jun;232:13-36. doi: 10.1016/j.trsl.2020.12.007. Epub 2020 Dec 19.
8
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.羟氯喹在预防新型冠状病毒感染方面的争议使风湿病学家站在了前沿。
RMD Open. 2020 Oct;6(3). doi: 10.1136/rmdopen-2020-001323.
9
Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer .对辛格所著《羟氯喹对狼疮和类风湿关节炎患者预防新冠病毒无效》的回应
Ann Rheum Dis. 2022 Aug 11;81(9):e162. doi: 10.1136/annrheumdis-2020-218683.